Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | MC1R | Q01726 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149137 | 1.00 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149136 | 1.00 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149962 | 0.95 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149963 | 0.95 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149964 | 0.95 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149140 | 0.93 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149141 | 0.93 | GPR119 (0.38) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL149552 | 0.91 | GPR119 (0.38) | GPR119KCNH2GPR183RET | |
| SCHEMBL121467 | 0.91 | GPR119 (0.38) | GPR119KCNH2GPR183RET | |
| SCHEMBL148618 | 0.87 | GPR119 (0.36) | GPR119KCNH2GPR183RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885KCNH2 2010/4885GPR183 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.